Metabolic research has moved through a rapid evolution in the past decade — from single GLP-1 receptor agonists, to dual GLP-1/GIP agonists, and now to triple agonists that simultaneously engage a third pathway through the glucagon receptor. Each generation has added complexity and, in clinical trials, incrementally larger effects on the metabolic outcomes being studied.
The GLP-1 Receptor: Where Modern Metabolic Research Started
GLP-1 is an incretin hormone secreted by intestinal L cells in response to nutrient ingestion. Its receptor activation stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central nervous system signalling. GLP-1 receptor agonists established the foundation for the receptor-targeting approach that subsequent generations have built upon — but single-pathway agonism doesn't capture the full range of metabolic regulation that researchers are now studying.
Adding GIP: The Dual Agonist Advance
GIP receptor activation produces synergistic effects with GLP-1 agonism on insulin secretion, with additional effects on adipose tissue and bone metabolism that GLP-1 alone does not produce. Dual GIP/GLP-1 agonism showed in Phase 3 trials that combining the two receptor pathways produced larger metabolic effects than either alone.
The Glucagon Receptor: The Triple Agonist Frontier
Glucagon receptor activation increases energy expenditure, stimulates fat oxidation in the liver, and reduces hepatic fat accumulation — effects that complement the insulin-sensitising properties of GIP and GLP-1 agonism. This is the rationale behind triple agonism and what makes compounds like retatrutide of particular interest to metabolic researchers. Research-grade retatrutide peptide is available from Australian suppliers for in vitro laboratory study of these mechanisms.
Where Triple Agonist Research Is Heading
The Phase 3 TRIUMPH programme has covered obesity, type 2 diabetes, knee osteoarthritis, liver disease, cardiovascular outcomes, and sleep apnoea — a breadth that reflects the multi-system reach of triple receptor agonism. With Phase 3 data continuing to emerge and the compound at over 500% year-on-year growth in research interest, triple agonist mechanisms represent one of the most actively studied areas in metabolic science in 2026.
